Search
                    COPD Paid Clinical Trials in Texas
A listing of 16  COPD  clinical trials  in Texas  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 16
        
                The state of Texas currently has 16 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin. 
            
                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
                                
            
            
        Recruiting
                            
            
                This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Research Site, Boerne, Texas  +11 locations         
        
        
            Conditions: Chronic Obstructive Pulmonary Disease (COPD)
        
            
        
    
                
                                    A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
                                
            
            
        Recruiting
                            
            
                This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 80 years
            Trial Updated:
                08/20/2025
            
            Locations: Research Site, Abilene, Texas  +33 locations         
        
        
            Conditions: COPD (Chronic Obstructive Pulmonary Disease)
        
            
        
    
                
                                    Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
                                
            
            
        Recruiting
                            
            
                The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory symptoms) and function (e.g., lung function, and six-minute walking test \[6MWT\]) after switching to THS compared to continuing to smoking cigarettes.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/07/2025
            
            Locations: Prolato Research LLC., Houston, Texas  +3 locations         
        
        
            Conditions: COPD, Smoking, Tobacco Use
        
            
        
    
                
                                    A Study to Evaluate Solrikitug in Participants With COPD (ZION)
                                
            
            
        Recruiting
                            
            
                A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 75 years
            Trial Updated:
                08/07/2025
            
            Locations: Research Site 016, Boerne, Texas  +3 locations         
        
        
            Conditions: COPD
        
            
        
    
                
                                    An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
                                
            
            
        Recruiting
                            
            
                This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 80 years
            Trial Updated:
                08/05/2025
            
            Locations: University of Texas Southwestern, Dallas, Texas         
        
        
            Conditions: Emphysema, Pulmonary, Emphysema or COPD
        
            
        
    
                
                                    A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
                                
            
            
        Recruiting
                            
            
                This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                08/04/2025
            
            Locations: DM Clinical Research, Tomball, Texas         
        
        
            Conditions: Asthma, COPD (Chronic Obstructive Pulmonary Disease)
        
            
        
    
                
                                    A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
                                
            
            
        Recruiting
                            
            
                This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 80 years
            Trial Updated:
                08/01/2025
            
            Locations: FutureSearch Trials of Neurology, Austin, Texas  +13 locations         
        
        
            Conditions: Chronic Obstructive Pulmonary Disease (COPD)
        
            
        
    
                
                                    Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
                                
            
            
        Recruiting
                            
            
                Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 130 years
            Trial Updated:
                07/31/2025
            
            Locations: Research Site, Amarillo, Texas  +8 locations         
        
        
            Conditions: Chronic Obstructive Pulmonary Disease (COPD)
        
            
        
    
                
                                    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
                                
            
            
        Recruiting
                            
            
                A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 80 years
            Trial Updated:
                07/23/2025
            
            Locations: Research Site, Boerne, Texas  +6 locations         
        
        
            Conditions: Chronic Obstructive Pulmonary Disease (COPD)
        
            
        
    
                
                                    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
                                
            
            
        Recruiting
                            
            
                A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 80 years
            Trial Updated:
                07/22/2025
            
            Locations: Research Site, Dallas, Texas  +4 locations         
        
        
            Conditions: Chronic Obstructive Pulmonary Disease (COPD)
        
            
        
    
                
                                    Heat Waves and the Elderly With COPD
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to investigate thermoregulatory responses in older individuals with COPD.             
        
        
    Gender:
                ALL
            Ages:
                65 years and above
            Trial Updated:
                03/04/2025
            
            Locations: Texas Health Presbyterian Hospital Dallas, Dallas, Texas         
        
        
            Conditions: COPD, Aging, Hyperthermia
        
            
        
    
                
                                    MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
                                
            
            
        Recruiting
                            
            
                Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.             
        
        
    Gender:
                ALL
            Ages:
                30 years and above
            Trial Updated:
                02/05/2025
            
            Locations: Respire Research Institute, Houston, Texas         
        
        
            Conditions: COPD
        
            
        
    1 - 12 of 16
            